{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "Diminazene aceturate", "SARS-CoV-2"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "36116513", "DateCompleted": {"Year": "2022", "Month": "10", "Day": "12"}, "DateRevised": {"Year": "2022", "Month": "12", "Day": "16"}, "Article": {"ArticleDate": [{"Year": "2022", "Month": "09", "Day": "15"}], "Language": ["eng"], "ELocationID": ["10.1016/j.cbi.2022.110161", "S0009-2797(22)00366-0"], "Journal": {"ISSN": "1872-7786", "JournalIssue": {"Volume": "367", "PubDate": {"Year": "2022", "Month": "Nov", "Day": "01"}}, "Title": "Chemico-biological interactions", "ISOAbbreviation": "Chem Biol Interact"}, "ArticleTitle": "Antiviral potential of diminazene aceturate against SARS-CoV-2 proteases using computational and in vitro approaches.", "Pagination": {"StartPage": "110161", "MedlinePgn": "110161"}, "Abstract": {"AbstractText": ["Diminazene aceturate (DIZE), an antiparasitic, is an ACE2 activator, and studies show that activators of this enzyme may be beneficial for COVID-19, disease caused by SARS-CoV-2. Thus, the objective was to evaluate the in silico and in vitro affinity of diminazene aceturate against molecular targets of SARS-CoV-2. 3D structures from DIZE and the proteases from SARS-CoV-2, obtained through the Protein Data Bank and Drug Database (Drubank), and processed in computer programs like AutodockTools, LigPlot, Pymol for molecular docking and visualization and GROMACS was used to perform molecular dynamics. The results demonstrate that DIZE could interact with all tested targets, and the best binding energies were obtained from the interaction of Protein S (closed conformation -7.87\u00a0kcal/mol) and M<sub>pro</sub> (-6.23\u00a0kcal/mol), indicating that it can act both by preventing entry and viral replication. The results of molecular dynamics demonstrate that DIZE was able to promote a change in stability at the cleavage sites between S1 and S2, which could prevent binding to ACE2 and fusion with the membrane. In addition, in vitro tests confirm the in silico results showing that DIZE could inhibit the binding between the spike receptor-binding domain protein and ACE2, which could promote a reduction in the virus infection. However, tests in other experimental models with in vivo approaches are needed."], "CopyrightInformation": "Copyright \u00a9 2022 Elsevier B.V. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (LAFIDG), Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil; Medicinal Plants Research Center (NPPM), Federal University of Piau\u00ed, Teresina, Brazil."}], "LastName": "Santos", "ForeName": "Esley S", "Initials": "ES"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (LAFIDG), Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil."}], "LastName": "Silva", "ForeName": "Priscila C", "Initials": "PC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Medicinal Chemistry and Biotechnology, QUIMEBIO, Federal University of Maranh\u00e3o, S\u00e3o Bernardo, MA, Brazil; Biodiversity and Biotechnology Research Center, BIOTEC, Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil."}], "LastName": "Sousa", "ForeName": "Paulo S A", "Initials": "PSA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Postgraduate Program in Medical Sciences, Federal University of Cear\u00e1, Fortaleza, CE, Brazil."}], "LastName": "Aquino", "ForeName": "Cristhyane C", "Initials": "CC"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (LAFIDG), Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil; Medicinal Plants Research Center (NPPM), Federal University of Piau\u00ed, Teresina, Brazil."}], "LastName": "Pacheco", "ForeName": "Gabriella", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (LAFIDG), Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil; Biodiversity and Biotechnology Research Center, BIOTEC, Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil."}], "LastName": "Teixeira", "ForeName": "Luiz F L S", "Initials": "LFLS"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Biodiversity and Biotechnology Research Center, BIOTEC, Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil."}], "LastName": "Araujo", "ForeName": "Alyne R", "Initials": "AR"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (LAFIDG), Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil."}], "LastName": "Sousa", "ForeName": "Francisca B M", "Initials": "FBM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Laboratory in Information Systems, Department of Information, Environment, Health and Food Production, Federal Institute of Piau\u00ed, LaPeSI/IFPI, Teresina, Piau\u00ed, Brazil."}], "LastName": "Barros", "ForeName": "Romulo O", "Initials": "RO"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Research Laboratory in Information Systems, Department of Information, Environment, Health and Food Production, Federal Institute of Piau\u00ed, LaPeSI/IFPI, Teresina, Piau\u00ed, Brazil."}], "LastName": "Ramos", "ForeName": "Ricardo M", "Initials": "RM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Medicinal Chemistry and Biotechnology, QUIMEBIO, Federal University of Maranh\u00e3o, S\u00e3o Bernardo, MA, Brazil; Biodiversity and Biotechnology Research Center, BIOTEC, Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil."}], "LastName": "Rocha", "ForeName": "Jefferson A", "Initials": "JA"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (LAFIDG), Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil; Biodiversity and Biotechnology Research Center, BIOTEC, Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil."}], "LastName": "Nicolau", "ForeName": "Lucas A D", "Initials": "LAD"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Laboratory of Pharmacology of Inflammation and Gastrointestinal Disorders (LAFIDG), Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil; Medicinal Plants Research Center (NPPM), Federal University of Piau\u00ed, Teresina, Brazil; Biodiversity and Biotechnology Research Center, BIOTEC, Post-graduation Program in Biotechnology, Parna\u00edba Delta Federal University, Parna\u00edba, PI, Brazil. Electronic address: jandvenes@ufpi.edu.br."}], "LastName": "Medeiros", "ForeName": "Jand V R", "Initials": "JVR"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Ireland", "MedlineTA": "Chem Biol Interact", "NlmUniqueID": "0227276", "ISSNLinking": "0009-2797"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Antiparasitic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Antiviral Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Protein S"}, {"RegistryNumber": "EC 3.4.-", "NameOfSubstance": "Peptide Hydrolases"}, {"RegistryNumber": "EC 3.4.15.1", "NameOfSubstance": "Peptidyl-Dipeptidase A"}, {"RegistryNumber": "EC 3.4.17.23", "NameOfSubstance": "Angiotensin-Converting Enzyme 2"}, {"RegistryNumber": "JI8SAD85NO", "NameOfSubstance": "diminazene aceturate"}, {"RegistryNumber": "Y5G36EEA5Z", "NameOfSubstance": "Diminazene"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Angiotensin-Converting Enzyme 2"}, {"QualifierName": [], "DescriptorName": "Antiparasitic Agents"}, {"QualifierName": ["chemistry", "pharmacology"], "DescriptorName": "Antiviral Agents"}, {"QualifierName": ["analogs & derivatives"], "DescriptorName": "Diminazene"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Molecular Docking Simulation"}, {"QualifierName": [], "DescriptorName": "Peptide Hydrolases"}, {"QualifierName": ["chemistry"], "DescriptorName": "Peptidyl-Dipeptidase A"}, {"QualifierName": [], "DescriptorName": "Protein S"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}, {"QualifierName": [], "DescriptorName": "COVID-19 Drug Treatment"}], "CoiStatement": "Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Rothan H.A., Byrareddy S.N. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J. Autoimmun. 2020 doi: 10.1016/j.jaut.2020.102433.", "ArticleIdList": ["10.1016/j.jaut.2020.102433", "PMC7127067", "32113704"]}, {"Citation": "Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., Cheng Z., Yu T., Xia J., Wei Y., Wu W., Xie X., Yin W., Li H., Cao B. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506. doi: 10.1016/S0140-6736(20)30183-5.", "ArticleIdList": ["10.1016/S0140-6736(20)30183-5", "PMC7159299", "31986264"]}, {"Citation": "OF THE INTERNATIONAL, Coronaviridae Study Group et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 2020;5(4):536. doi: 10.1038/s41564-020-0695-z.", "ArticleIdList": ["10.1038/s41564-020-0695-z", "PMC7095448", "32123347"]}, {"Citation": "Vaduganathan M., Vardeny O., Michel T. Original: renin\u2013angiotensin\u2013aldosterone system inhibitors in patients with covid. Cell. 2020 doi: 10.1056/NEJMsr2005760.", "ArticleIdList": ["10.1056/NEJMsr2005760", "PMC7121452", "32227760"]}, {"Citation": "Perlot T., Penninger J.M. ACE2\u2013From the renin\u2013angiotensin system to gut microbiota and malnutrition. Microb. Infect. 2013;15(13):866\u2013873. doi: 10.1016/j.micinf.2013.08.003.", "ArticleIdList": ["10.1016/j.micinf.2013.08.003", "PMC7110844", "23962453"]}, {"Citation": "Kulemina L.V., Ostrov D.A. Prediction of off-target effects on angiotensin-converting enzyme 2. J. Biomol. Screen. 2011;16(8):878\u2013885. doi: 10.1177/1087057111413919.", "ArticleIdList": ["10.1177/1087057111413919", "21859683"]}, {"Citation": "Nicolau L.A.D., Nol\u00eato I.R.S.G., Medeiros J.V.R. Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight. Expet Rev. Clin. Pharmacol. 2020;13(8):807\u2013811. doi: 10.1080/17512433.2020.1798760.", "ArticleIdList": ["10.1080/17512433.2020.1798760", "PMC7441754", "32686527"]}, {"Citation": "Zhu Z., Lian X., Su X., Wu W., Marraro G.A., Zeng Y. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir. Res. 2020;21(1):1\u201314. doi: 10.1186/s12931-020-01479-w.", "ArticleIdList": ["10.1186/s12931-020-01479-w", "PMC7450684", "32854739"]}, {"Citation": "Burgue\u00f1o J.F., Reich A., Hazime H., Quintero M.A., Fernandez I., Fritsch J., Santander A.M., Brito N., Damas O.M., Deshpande A., Kerman D.H., Zhang L., Gao Z., Ban Y., Wang L., Pignac-Kobinger J., Abreu M.T. Expression of SARS-CoV 2 entry molecules ACE2 and TMPRSS2 in the gut of patients with IBD. Inflamm. Bowel Dis. 2020;26(6):797\u2013808. doi: 10.1093/ibd/izaa085.", "ArticleIdList": ["10.1093/ibd/izaa085", "PMC7188157", "32333601"]}, {"Citation": "Sorokina M., Teixeira J.M., Barrera-Vilarmau S., Paschke R., Papasotiriou I., Rodrigues J.P., Kastritis P.L. Structural models of human ACE2 variants with SARS-CoV 2 Spike protein for structure-based drug design. Sci. Data. 2020;7(1):1\u201310. doi: 10.6084/m9.figshare.12902498.", "ArticleIdList": ["10.6084/m9.figshare.12902498", "PMC7494880", "32938937"]}, {"Citation": "Liu T., Luo S., Libby P., Shi G.P. Cathepsin L-selective inhibitors: a potentially promising treatment for COVID-19 patients. Pharmacol. Therapeut. 2020;213 doi: 10.1016/j.pharmthera.2020.107587.", "ArticleIdList": ["10.1016/j.pharmthera.2020.107587", "PMC7255230", "32470470"]}, {"Citation": "Zhang X., Zhou Y., Yu X., Huang Q., Fang W., Li J., Bonventre J.V., Sukhova G.K., Libby P., Shi G.P. Differential roles of cysteinyl cathepsins in TGF-\u03b2 signaling and tissue fibrosis. iScience. 2019;19:607\u2013622. doi: 10.1016/j.isci.2019.08.014.", "ArticleIdList": ["10.1016/j.isci.2019.08.014", "PMC6715892", "31446224"]}, {"Citation": "Gheblawi M., Wang K., Viveiros A., Nguyen Q., Zhong J.C., Turner A.J., Raizada M.K., Grant M.B., Oudit G.Y. Angiotensin-converting enzyme 2: SARS-CoV 2 receptor and regulator of the renin-angiotensin system: celebrating the 20th anniversary of the discovery of ACE2. Circ. Res. 2020;126(10):1456\u20131474. doi: 10.1161/CIRCRESAHA.120.317015.", "ArticleIdList": ["10.1161/CIRCRESAHA.120.317015", "PMC7188049", "32264791"]}, {"Citation": "Schumacher N., Rose-John S. Adam17 activity and IL-6 trans-signaling in inflammation and cancer. Cancers. 2019;11(11):1736. doi: 10.3390/cancers11111736.", "ArticleIdList": ["10.3390/cancers11111736", "PMC6895846", "31694340"]}, {"Citation": "Hegyi A., Ziebuhr J. Conservation of substrate specificities among coronavirus main proteases. J. Gen. Virol. 2002;83(3):595\u2013599. doi: 10.1099/0022-1317-83-3-595.", "ArticleIdList": ["10.1099/0022-1317-83-3-595", "11842254"]}, {"Citation": "Rut W., Groborz K., Zhang L., Sun X., Zmudzinski M., Pawlik B., Wang X., Jochmans D., Neyts J., Mlynarski W., Hilgenfeld M., Drag M. SARS-CoV-2 M pro inhibitors and activity-based probes for patient-sample imaging. Nat. Chem. Biol. 2021;17(2):222\u2013228. doi: 10.1038/s41589-020-00689-z.", "ArticleIdList": ["10.1038/s41589-020-00689-z", "33093684"]}, {"Citation": "Ullrich S., Nitsche C. The SARS-CoV 2 main protease as drug target. Bioorg. Med. Chem. Lett. 2020 doi: 10.1016/j.bmcl.2020.127377.", "ArticleIdList": ["10.1016/j.bmcl.2020.127377", "PMC7331567", "32738988"]}, {"Citation": "Nicolau L.A.D., Magalh\u00e3es P.J.C., Vale M.L. What would S\u00e9rgio Ferreira say to your physician in this war against COVID-19: how about kallikrein/kinin system? Med. Hypotheses. 2020;143 doi: 10.1016/j.mehy.2020.109886.", "ArticleIdList": ["10.1016/j.mehy.2020.109886", "PMC7261103", "32504925"]}, {"Citation": "Miller D.M., Swan G.E., Lobetti R.G., Jacobson L.S. The pharmacokinetics of diminazene ceturate after intramuscular administration in healthy dogs. J. South Afr. Vet. Assoc. 2005;76(3):146\u2013150.", "ArticleIdList": ["16300182"]}, {"Citation": "Qi Y., Zhang J., Cole-Jeffrey C.T., Shenoy V., Espejo A., Hanna M., Chunjuan C., Pepine C.J., Katovich M.J., Raizada M.K. Diminazene aceturate enhances angiotensin-converting enzyme 2 activity and attenuates ischemia-induced cardiac pathophysiology. Hypertension. 2013;62(4):746\u2013752. doi: 10.1161/HYPERTENSIONAHA.113.01337.", "ArticleIdList": ["10.1161/HYPERTENSIONAHA.113.01337", "PMC3881360", "23959549"]}, {"Citation": "Shenoy V., Gjymishka A., Jarajapu Y.P., Qi Y., Afzal A., Rigatto K., Ferreira A.J., Fraga-Silva R.A., Kearns P., Douglas J.Y., Agarwal D., Mubarak K.K., Bradford C., Kennedy W.R., Joo Y., Rathinasabapathy A., Bruce E., Gupta D., Cardounel A.J., Mocco J., Patel J.M., Francis J., Grant M.B., Katovich M.J., Raizada M.K. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am. J. Respir. Crit. Care Med. 2013;187(6):648\u2013657. doi: 10.1164/rccm.201205-0880OC.", "ArticleIdList": ["10.1164/rccm.201205-0880OC", "PMC3733435", "23370913"]}, {"Citation": "Kuriakose S., Muleme H.M., Onyilagha C., Singh R., Jia P., Uzonna J.E. Diminazene aceturate (Berenil) modulates the host cellular and inflammatory responses to Trypanosoma congolense infection. PLoS One. 2012;7(11) doi: 10.1371/journal.pone.0048696.", "ArticleIdList": ["10.1371/journal.pone.0048696", "PMC3492428", "23144931"]}, {"Citation": "Kuriakose S., Muleme H., Onyilagha C., Okeke E., Uzonna J.E. Diminazene aceturate (Berenil) modulates LPS induced pro-inflammatory cytokine production by inhibiting phosphorylation of MAPKs and STAT proteins. Innate Immun. 2014;20(7):760\u2013773. doi: 10.1177/1753425913507488.", "ArticleIdList": ["10.1177/1753425913507488", "24179040"]}, {"Citation": "Marilda L.A.D.M., Liliane D.A., Rodrigo A.F.-S., Let\u00edcia A.S.P., Heder J.R., Gustavo B.M., Vinayak S., Mohan K.R., Anderson J.F. Anti-hypertensive effects of diminazene aceturate: an angiotensin- converting enzyme 2 activator in rats. Protein Pept. Lett. 2016;23:9\u201316.", "ArticleIdList": ["26458404"]}, {"Citation": "Panahi Y., Dadkhah M., Talei S., Gharari Z., Asghariazar V., Abdolmaleki A., Matin S., Molaei S. Can anti-parasitic drugs help control COVID-19? Future Virol. 2022 May;17(5):315\u2013339.", "ArticleIdList": ["PMC8940209", "35359702"]}, {"Citation": "Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 2000;28(1):235\u2013242. doi: 10.1093/nar/28.1.235.", "ArticleIdList": ["10.1093/nar/28.1.235", "PMC102472", "10592235"]}, {"Citation": "Goodsell D.S. Computational docking of biomolecular complexes with AutoDock. Cold Spring Harb. Protoc. 2009;2009(5) p. pdb. prot5200. 10.1101/pdb.prot5200.", "ArticleIdList": ["20147154"]}, {"Citation": "Goodsell D.S., Morris G.M., Olson A.J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recogn. 1996;9(1):1\u20135. doi: 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6.", "ArticleIdList": ["10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO;2-6", "8723313"]}, {"Citation": "Morris G.M., Huey R., Olson A.J. Using autodock for ligand\u2010receptor docking. Curr. Protocols Bioinf. 2008;24(1):8. doi: 10.1002/0471250953.bi0814s24. 14. 1-8.14. 40.", "ArticleIdList": ["10.1002/0471250953.bi0814s24", "19085980"]}, {"Citation": "Sanner M.F. Python: a programming language for software integration and development. J. Mol. Graph. Model. 1999;17(1):57\u201361.", "ArticleIdList": ["10660911"]}, {"Citation": "Gasteiger J., Marsili M. Iterative partial equalization of orbital electronegativity\u2014a rapid access to atomic charges. Tetrahedron. 1980;36(22):3219\u20133228. doi: 10.1016/0040-4020(80)80168-2.", "ArticleIdList": ["10.1016/0040-4020(80)80168-2"]}, {"Citation": "Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 1998;19(14):1639\u20131662. doi: 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B.", "ArticleIdList": ["10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B"]}, {"Citation": "Solis F.J., Wets R.J.B. Minimization by random search techniques. Math. Oper. Res. 1981;6(1):19. doi: 10.1287/moor.6.1.19. 3.", "ArticleIdList": ["10.1287/moor.6.1.19"]}, {"Citation": "Rocha J.A., Rego N.C., Carvalho B.T., Silva F.I., Sousa J.A., Ramos R.M., Passos I.N.G., Moraes J., Leite J.R.S.A., Lima F.C. Computational quantum chemistry, molecular docking, and ADMET predictions of imidazole alkaloids of Pilocarpus microphyllus with schistosomicidal properties. PLoS One. 2018;13(6) doi: 10.1371/journal.pone.0198476.", "ArticleIdList": ["10.1371/journal.pone.0198476", "PMC6019389", "29944674"]}, {"Citation": "Oostenbrink C., Villa A., Mark A.E., Van Gunsteren W.F. A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force\u2010field parameter sets 53A5 and 53A6. J. Comput. Chem. 2004;25(13):1656\u20131676. doi: 10.1002/jcc.20090.", "ArticleIdList": ["10.1002/jcc.20090", "15264259"]}, {"Citation": "Abraham M.J., Van Der Spoel D., Lindahl E., Hess B. The GROMACS development team. GROMACS user manual version. 2018. www.gromacs.org 1."}, {"Citation": "Arcanjo D.D., Vasconcelos A.G., Nascimento L.A., Mafud A.C., Pl\u00e1cido A., Alves M.M., Delerue-Matos C., Bemquerer M.P., Vale N., Gomes P., Oliveira E.B., Lima F.C.A., Mascarenhas Y.P., Carvalho F.A., Simonsen U., Ramos R.M., Leite J.R.S. Structure-function studies of BPP-BrachyNH2 and synthetic analogues thereof with Angiotensin I-Converting Enzyme. Eur. J. Med. Chem. 2017;139:401\u2013411. doi: 10.1016/j.ejmech.2017.08.019.", "ArticleIdList": ["10.1016/j.ejmech.2017.08.019", "28810191"]}, {"Citation": "Waterhouse A., Bertoni M., Bienert S., Studer G., Tauriello G., Gumienny R., Heer F.T., Beer T.A.P., Rempfer C., Bordoli L., Lepore R., Schwede T. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296\u2013W303. doi: 10.1093/nar/gky427.", "ArticleIdList": ["10.1093/nar/gky427", "PMC6030848", "29788355"]}, {"Citation": "Gordon J.C., Myers J.B., Folta T., Shoja V., Heath L.S., Onufriev A. H++: a server for estimating p K as and adding missing hydrogens to macromolecules. Nucleic Acids Res. 2005;33(suppl_2):W368\u2013W371. doi: 10.1093/nar/gki464.", "ArticleIdList": ["10.1093/nar/gki464", "PMC1160225", "15980491"]}, {"Citation": "Stroet M., Caron B., Visscher K.M., Geerke D.P., Malde A.K., Mark A.E. Automated topology builder version 3.0: prediction of solvation free enthalpies in water and hexane. J. Chem. Theor. Comput. 2018;14(11):5834\u20135845. doi: 10.1021/acs.jctc.8b00768.", "ArticleIdList": ["10.1021/acs.jctc.8b00768", "30289710"]}, {"Citation": "Laskowski R.A., Swindells M.B. LigPlot+: multiple ligand\u2013protein interaction diagrams for drug discovery. J. Chem. Inf. Model. 2011;51(10):2778\u20132786. doi: 10.1021/ci200227u.", "ArticleIdList": ["10.1021/ci200227u", "21919503"]}, {"Citation": "Ramos R.M., Perez J.M., Baptista L.A., de Amorim H.L.N. Interaction of wild type, G68R and L125M isoforms of the arylamine-N-acetyltransferase from Mycobacterium tuberculosis with isoniazid: a computational study on a new possible mechanism of resistance. J. Mol. Model. 2012;18(9):4013\u20134024. doi: 10.1007/s00894-012-1383-6.", "ArticleIdList": ["10.1007/s00894-012-1383-6", "22460521"]}, {"Citation": "Chakraborty C., Sharma A.R., Sharma G., Bhattacharya M., Lee S.S. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): diagnostic and proposed therapeutic options. Eur. Rev. Med. Pharmacol. Sci. 2020;24(7):4016\u20134026. doi: 10.26355/eurrev_202004_20871.", "ArticleIdList": ["10.26355/eurrev_202004_20871", "32329877"]}, {"Citation": "Alexpandi R., De Mesquita J.F., Pandian S.K., Ravi A.V. Quinolines-based SARS-CoV 2 3CLpro and RdRp inhibitors and Spike-RBD-ACE2 inhibitor for drug-repurposing against COVID-19: na in silico analysis. Front. Microbiol. 2020;11:1796. doi: 10.3389/fmicb.2020.01796.", "ArticleIdList": ["10.3389/fmicb.2020.01796", "PMC7390959", "32793181"]}, {"Citation": "Tu Y.F., Chien C.S., Yarmishyn A.A., Lin Y.Y., Luo Y.H., Lin Y.T., Lai W.Y., Yang D.M., Chou S.J., Yang Y.P., Wang M.L., Chiou S.H. A review of SARS-CoV 2 and the ongoing clinical trials. Int. J. Mol. Sci. 2020;21(7):2657. doi: 10.3390/ijms21072657.", "ArticleIdList": ["10.3390/ijms21072657", "PMC7177898", "32290293"]}, {"Citation": "Pushpakom S., Iorio F., Eyers P.A., Escott K.J., Hopper S., Wells A., Doig A., Guilliams T., Latimer J., McNamee C., Norris A., Sanseau P., Cavalla D., Pirmohamed M. Drug repurposing: progress, challenges and recommendations. Nat. Rev. Drug Discov. 2019;18(1):41\u201358.", "ArticleIdList": ["30310233"]}, {"Citation": "Ton A.-T., Gentile F., Hsing M., Ban F., Cherkasov A. Rapid identification of potential inhibitors of SARS\u2010CoV\u20102 main protease by deep docking of 1.3 billion compounds. Mol. Inf. 2022;39(8):e2000028. doi: 10.1002/minf.202000028.", "ArticleIdList": ["10.1002/minf.202000028", "PMC7228259", "32162456"]}, {"Citation": "Hutchinson M.P., Watson H.J.C. Berenil in the treatment of Trypanosoma gambiense infection in man. Trans. R. Soc. Trop. Med. Hyg. 1962;56(3):227\u2013230.", "ArticleIdList": ["14450244"]}, {"Citation": "Abaru D.E., Liwo D.A., Isakina D., Okori E.E. Retrospective long-term study of effects of berenil by follow-up of patients treated since 1965. Tropenmed. Parasitol. 1984;35(3):148\u2013150.", "ArticleIdList": ["6495383"]}, {"Citation": "Fang L., Karakiulakis G., Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 2020;8(4):e21. doi: 10.1016/S2213-2600(20)30116-8.", "ArticleIdList": ["10.1016/S2213-2600(20)30116-8", "PMC7118626", "32171062"]}, {"Citation": "Diaz J.H. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe. J. Trav. Med. 2020;382:1653\u20131659. doi: 10.1093/jtm/taaa041.", "ArticleIdList": ["10.1093/jtm/taaa041", "PMC7184445", "32186711"]}, {"Citation": "Pang X., Cui Y., Zhu Y. Recombinant human ACE2: potential therapeutics of SARS-CoV-2 infection and its complication. Acta Pharmacol. Sin. 2020;41(9):1255\u20131257. doi: 10.1038/s41401-020-0430-6.", "ArticleIdList": ["10.1038/s41401-020-0430-6", "PMC7313652", "32581256"]}, {"Citation": "Rodr\u00edguez\u2010Puertas R. ACE2 activators for the treatment of COVID 19 patients. J. Med. Virol. 2020;92(10):1701\u20131702. doi: 10.1002/jmv.25992.", "ArticleIdList": ["10.1002/jmv.25992", "PMC7267413", "32379346"]}, {"Citation": "Ortega J.T., Serrano M.L., Jastrzebska B. Class AG protein-coupled receptor antagonist famotidine as a therapeutic alternative against SARS-CoV 2: an in silico analysis. Biomolecules. 2020;10(6):954. doi: 10.3390/biom10060954.", "ArticleIdList": ["10.3390/biom10060954", "PMC7355875", "32599963"]}, {"Citation": "Matsoukas J.M., Gadanec K.L., Zulli A., Apostolopoulos V., Konstantinos K., Ligielli I., Moschovou K., Georgiou N., Plotas P., Chasapis C.T., Moore G., Ridgway H., Mavromoustakos T. Diminazene aceturate reduces angiotensin II constriction and interacts with the spike protein of severe acute respiratory syndrome coronavirus 2. Biomedicines. 2022;10(7):1731. doi: 10.3390/biomedicines10071731.", "ArticleIdList": ["10.3390/biomedicines10071731", "PMC9312513", "35885036"]}, {"Citation": "Chen D., Oezguen N., Urvil P., Ferguson C., Dann S.M., Savidge T.C. Regulation of protein-ligand binding affinity by hydrogen bond pairing. Sci. Adv. 2016;2(3) doi: 10.1126/sciadv.1501240.", "ArticleIdList": ["10.1126/sciadv.1501240", "PMC4820369", "27051863"]}, {"Citation": "Raj S., Sasidharan S., Dubey V.K., Saudagar P. Identification of lead molecules against potential drug target protein MAPK4 from L. donovani: an in-silico approach using docking, molecular dynamics and binding free energy calculation. PLoS One. 2019;14(8) doi: 10.1371/journal.pone.0221331.", "ArticleIdList": ["10.1371/journal.pone.0221331", "PMC6699710", "31425543"]}, {"Citation": "Tomic N., Pojskic L., Kalajdzic A., Ramic J., Kadric N.L., Ikanovic T., Maksimovic M., Pojskic N. Screening of preferential binding affinity of selected natural compounds to SARS-CoV 2 proteins using in silico methods. EJMO. 2020;4:319\u2013323. doi: 10.14744/ejmo.2020.72548.", "ArticleIdList": ["10.14744/ejmo.2020.72548"]}, {"Citation": "Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C., Duan Y., Yu J., Wang L., Xiao G., Rao Z., Yang H. Structure of M pro from SARS-CoV 2 and discovery of its inhibitors. Nature. 2020;582(7811):289\u2013293. doi: 10.1038/s41586-020-2223-y.", "ArticleIdList": ["10.1038/s41586-020-2223-y", "32272481"]}, {"Citation": "Estrada E. Topological analysis of SARS-CoV 2 main protease. Chaos: Interdiscip. J. Nonlinear Sci. 2020;30(6) doi: 10.1063/5.0013029.", "ArticleIdList": ["10.1063/5.0013029", "PMC7286701", "32611087"]}, {"Citation": "Chikhale R.V., Gupta V.K., Eldesoky G.E., Wabaidur S.M., Patil S.A., Islam M.A. Identification of potential anti-TMPRSS2 natural products through homology modelling, virtual screening and molecular dynamics simulation studies. J. Biomol. Struct. Dyn. 2020:1\u201316. doi: 10.1080/07391102.2020.1798813.", "ArticleIdList": ["10.1080/07391102.2020.1798813", "PMC7335809", "32741259"]}, {"Citation": "Gyebi G.A., Adegunloye A.P., Ibrahim I.M., Ogunyemi O.M., Afolabi S.O., Ogunro O.B. Prevention of SARS-CoV 2 cell entry: insight from in silico interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2. J. Biomol. Struct. Dyn. 2020:1\u201325. doi: 10.1080/07391102.2020.1835726.", "ArticleIdList": ["10.1080/07391102.2020.1835726", "PMC7594191", "33089728"]}, {"Citation": "Hoffmann M., Kleine-Weber H., Schroeder S., Kr\u00fcger N., Herrler T., Erichsen S., Schiergens T.S., Herrler G., Wu N.H., Nitsche A., M\u00fcller M.A., Drosten C., P\u00f6hlmann S. SARS-CoV 2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u2013280. doi: 10.1016/j.cell.2020.02.052. e8.", "ArticleIdList": ["10.1016/j.cell.2020.02.052", "PMC7102627", "32142651"]}, {"Citation": "Heurich A., Hofmann-Winkler H., Gierer S., Liepold T., Jahn O., P\u00f6hlmann S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J. Virol. 2014;88(2):1293\u20131307. doi: 10.1128/JVI.02202-13.", "ArticleIdList": ["10.1128/JVI.02202-13", "PMC3911672", "24227843"]}, {"Citation": "Palau V., Riera M., Soler M.J. ADAM17 inhibition may exert a protective effect on COVID-19. Nephrol. Dial. Transplant. 2020;35(6):1071\u20131072. doi: 10.1093/ndt/gfaa093.", "ArticleIdList": ["10.1093/ndt/gfaa093", "PMC7184459", "32291449"]}, {"Citation": "Murumkar P.R., Sharma M.K., Giridhar R., Yadav M.R. Virtual screening-based identification of lead molecules as selective TACE inhibitors. Med. Chem. Res. 2015;24(1):226\u2013244. doi: 10.1007/s00044-014-1097-7.", "ArticleIdList": ["10.1007/s00044-014-1097-7"]}, {"Citation": "Borah P.K., Chakraborty S., Jha A.N., Rajkhowa S., Duary R.K. In silico approaches and proportional odds model towards identifying selective adam17 inhibitors from anti-inflammatory natural molecules. J. Mol. Graph. Model. 2016;70:129\u2013139. doi: 10.1016/j.jmgm.2016.10.003. 2016.", "ArticleIdList": ["10.1016/j.jmgm.2016.10.003", "27723561"]}, {"Citation": "Braz H.L.B., de Moraes Silveira J.A., Marinho A.D., de Moraes M.E.A., de Moraes Filho M.O., Monteiro H.S.A., Jorge R.J.B. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV 2 infection. Int. J. Antimicrob. Agents. 2020;56(3) doi: 10.1016/j.ijantimicag.2020.106119.", "ArticleIdList": ["10.1016/j.ijantimicag.2020.106119", "PMC7390782", "32738306"]}, {"Citation": "Liu Z., Xiao X., Wei X., Li J., Yang J., Tan H., Zhu J., Zhang Q., Wu J., Liu L. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS\u2010CoV\u20102. J. Med. Virol. 2020;92(6):595\u2013601. doi: 10.1002/jmv.25726. 2020.", "ArticleIdList": ["10.1002/jmv.25726", "PMC7228221", "32100877"]}, {"Citation": "Vivek-Ananth R.P., Rana A., Rajan N., Biswal H.S., Samal A. In silico identification of potential natural product inhibitors of human proteases key to SARS-CoV-2 infection. Molecules. 2020;25(17):3822. doi: 10.3390/molecules25173822.", "ArticleIdList": ["10.3390/molecules25173822", "PMC7504347", "32842606"]}, {"Citation": "Hardegger L.A., Kuhn B., Spinnler B., Anselm L., Ecabert R., Stihle M., Gsell B., Thoma R., Diez J., Benz J., Plancher J.M., Hartmann G., Banner D.W., Haap W., Diederich F. Systematic investigation of halogen bonding in protein\u2013ligand interactions. Angew. Chem. Int. Ed. 2011;50(1):314\u2013318. doi: 10.1002/anie.201006781.", "ArticleIdList": ["10.1002/anie.201006781", "21184410"]}, {"Citation": "Walls A.C., Park Y.J., Tortorici M.A., Wall A., McGuire A.T., Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020;181(2):281\u2013292. doi: 10.1016/j.cell.2020.02.058. e6.", "ArticleIdList": ["10.1016/j.cell.2020.02.058", "PMC7102599", "32155444"]}, {"Citation": "Pal S., Talukdar A. 2020. Compilation of Potential Protein Targets for SARS-CoV 2: Preparation of Homology Model and Active Site Determination for Future Rational Antiviral Design.", "ArticleIdList": ["10.26434/chemrxiv.12084468.v1"]}, {"Citation": "Imai Y., Kuba K., Rao S., Huan Y., Guo F., Guan B., Yang P., Sarao R., Wada T., Crackower M.A., Hein L., Jiang C., Penninger J.M. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112\u2013116. doi: 10.1038/nature03712.", "ArticleIdList": ["10.1038/nature03712", "PMC7094998", "16001071"]}, {"Citation": "Potere N., Batticciotto A., Vecchi\u00e9 A., Porreca E., Cappelli A., Abbate A., Dentali F., Bonaventura A. The role of IL-6 and IL-6 blockade in COVID-19. Expet Rev. Clin. Immunol. 2021:1\u201317. doi: 10.1080/1744666X.2021.1919086.", "ArticleIdList": ["10.1080/1744666X.2021.1919086", "33874829"]}, {"Citation": "Mart\u00ednez L. Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis. PLoS One. 2015;10(3) doi: 10.1371/journal.pone.0119264.", "ArticleIdList": ["10.1371/journal.pone.0119264", "PMC4376797", "25816325"]}, {"Citation": "Ou X., Liu Y., Lei X., Li P., Mi D., Ren L., Guo L., Chen T., Hu J., Xiang Z., Mu Z., Chen X., Wang J., Qian Z. 2020. Characterization of Spike Glycoprotein of 2019-nCoV on Virus Entry and its Immune Cross-Reactivity with Spike Glycoprotein of SARS-CoV.", "ArticleIdList": ["10.21203/rs.2.24016/v1", "PMC7100515", "32221306"]}, {"Citation": "Egieyeh S., Egieyeh E., Malan S., Christofells A., Fielding B. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2) PLoS One. 2021;16(1) doi: 10.1371/journal.pone.0245258.", "ArticleIdList": ["10.1371/journal.pone.0245258", "PMC7793299", "33417604"]}, {"Citation": "Kwon P.S., Oh H., Kwon S.J., Jin W., Zhang F., Fraser K., Hong J.J., Linhardt R.J., Dordick J.S. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro. Cell Discov. 2020;6(1):1\u20134. doi: 10.1038/s41421-020-00192-8.", "ArticleIdList": ["10.1038/s41421-020-00192-8", "PMC7378085", "32714563"]}, {"Citation": "Goc A., Niedzwiecki A., Rath M. Polyunsaturated \u03c9-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry. Sci. Rep. 2021;11(1):1\u201312. doi: 10.1038/s41598-021-84850-1.", "ArticleIdList": ["10.1038/s41598-021-84850-1", "PMC7933164", "33664446"]}, {"Citation": "Carino A., Moraca F., Fiorillo B., Marchian\u00f2 S., Sepe V., Biagioli M., Finamore C., Bozza S., Francisci D., Distrutti E., Catalanotti B., Zampella A., Fiorucci S. Hijacking SARS-CoV-2/ACE2 receptor interaction by natural and semi-synthetic steroidal agents acting on functional pockets on the receptor binding domain. Front. Chem. 2020;8:846. doi: 10.3389/fchem.2020.572885.", "ArticleIdList": ["10.3389/fchem.2020.572885", "PMC7645072", "33195060"]}, {"Citation": "Neufurth M., Wang X., Tolba E., Lieberwirth I., Wang S., Schr\u00f6der H.C., M\u00fcller W.E. The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations. Biochem. Pharmacol. 2020;182 doi: 10.1016/j.bcp.2020.114215.", "ArticleIdList": ["10.1016/j.bcp.2020.114215", "PMC7474874", "32905794"]}, {"Citation": "Maas M.N., Hintzen J.C., L\u00f6ffler P.M., Mecinovi\u0107 J. Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides. Chem. Commun. 2021;57(26):3283\u20133286. doi: 10.1039/D0CC08387A.", "ArticleIdList": ["10.1039/D0CC08387A", "33651072"]}, {"Citation": "Choy K., Wong A.Y., Kaewpreedee P., Sai S.F., Chen D., Hui K.P.Y., Chu D.K.W., Chan M.C.W., Cheung P. P. Huang, Peiris X., Yen M., Remdesivir H. lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antivir. Res. 2020;178 doi: 10.1016/j.antiviral.2020.104786.", "ArticleIdList": ["10.1016/j.antiviral.2020.104786", "PMC7127386", "32251767"]}, {"Citation": "Xu Y.-M., In\u00e1cio M.C., Liu M.X., Gutalilaka A.A.L. Discovery of diminazene as a dual inhibitor of SARS-CoV-2 human host proteases TMPRSS2 and furin using cell-based assays. Curr. Res. Chem. Biol. 2022;2 doi: 10.1016/j.crchbi.2022.100023.", "ArticleIdList": ["10.1016/j.crchbi.2022.100023", "PMC8920474", "35815069"]}, {"Citation": "Oliveira G.L.S., Freitas R.M. Diminazene aceturate\u2014an antiparasitic drug of antiquity: advances in pharmacology & therapeutics. Pharmacol. Res. 2015;102:138\u2013157. doi: 10.1016/j.phrs.2015.10.005.", "ArticleIdList": ["10.1016/j.phrs.2015.10.005", "26470648"]}, {"Citation": "Peregrine A.S., Mamman M. Pharmacology of diminazene: a review. Acta Trop. 1993;54(3\u20134):185\u2013203. doi: 10.1016/0001-706X(93)90092-P.", "ArticleIdList": ["10.1016/0001-706X(93)90092-P", "7902657"]}, {"Citation": "Gjymishka A., Kulemina L.V., Shenoy V., Katovich M., Ostrov D.A., Raizada M.K. Diminazene aceturate is an ACE2 activator and a novel antihypertensive drug. Faseb. J. 2010;24(3):1032\u20131033. doi: 10.1096/fasebj.24.1_supplement.1032.3. 1032.", "ArticleIdList": ["10.1096/fasebj.24.1_supplement.1032.3"]}, {"Citation": "Kate gadanec L., Qaradkhi T., McSweeney K.R., Ali B.A., Zulli A., Apostolopoulos V. Dual targeting of toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment. Future Microbiol. 2021;16(4):205\u2013209. doi: 10.2217/fmb-2021-0018.", "ArticleIdList": ["10.2217/fmb-2021-0018", "PMC7885526", "33569984"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "12", "Day": "2"}, {"Year": "2022", "Month": "8", "Day": "30"}, {"Year": "2022", "Month": "9", "Day": "1"}, {"Year": "2022", "Month": "9", "Day": "19", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "10", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2022", "Month": "9", "Day": "18", "Hour": "19", "Minute": "23"}, {"Year": "2022", "Month": "9", "Day": "15"}], "PublicationStatus": "ppublish", "ArticleIdList": ["36116513", "PMC9476334", "10.1016/j.cbi.2022.110161", "S0009-2797(22)00366-0"]}}], "PubmedBookArticle": []}